文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

嵌合抗原受体 T 细胞治疗后的神经毒性和细胞因子释放综合征：对机制和新型疗法的深入了解。

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.

机构信息

T Cell Engineering, Mayo Clinic, Rochester, MN, United States.

Division of Hematology, Mayo Clinic, Rochester, MN, United States.

出版信息

Front Immunol. 2020 Aug 28;11:1973. doi: 10.3389/fimmu.2020.01973. eCollection 2020.

DOI:10.3389/fimmu.2020.01973
PMID:32983132
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7485001/
Abstract

Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in treating certain relapsed/refractory hematological cancers. However, CART cell therapy is also associated with toxicities which present an obstacle to its wider adoption as a mainstay for cancer treatment. The primary toxicities following CART cell administration are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). New insights into the mechanisms of these toxicities have spurred novel treatment options. In this review, we summarize the available literature on the clinical manifestations, mechanisms, and treatments of CART-associated CRS and ICANS.

摘要

嵌合抗原受体 T (CART) 细胞免疫疗法在治疗某些复发/难治性血液系统癌症方面取得了显著成功。然而，CART 细胞治疗也与毒性相关，这成为其广泛应用于癌症治疗的主要障碍。CART 细胞给药后的主要毒性是细胞因子释放综合征 (CRS) 和免疫效应细胞相关神经毒性综合征 (ICANS)。对这些毒性机制的新认识促使出现了新的治疗选择。在这篇综述中，我们总结了关于 CART 相关 CRS 和 ICANS 的临床表现、机制和治疗的现有文献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f352/7485001/02754274d2a3/fimmu-11-01973-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f352/7485001/02754274d2a3/fimmu-11-01973-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f352/7485001/02754274d2a3/fimmu-11-01973-g001.jpg

相似文献

[1]
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.

Front Immunol. 2020

[2]
Reactions Related to CAR-T Cell Therapy.

Front Immunol. 2021

[3]
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.

Semin Immunopathol. 2024-7-16

[4]
Need for standardization of cytokine profiling in CAR T cell therapy.

Mol Ther. 2024-9-4

[5]
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.

Front Immunol. 2021

[6]
Management of T-Cell Engaging Immunotherapy Complications.

Cancer J. 2019

[7]
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.

J Exp Clin Cancer Res. 2021-11-18

[8]
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.

Intensive Care Med. 2024-9

[9]
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Expert Rev Hematol. 2019-3-18

[10]
Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.

J Cell Mol Med. 2021-12

引用本文的文献

[1]
Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation.

J Transl Med. 2025-7-25

[2]
Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells.

World J Gastrointest Oncol. 2025-7-15

[3]
[Biomaterials of different sizes for enhanced adoptive cell transfer therapy in solid tumors].

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025-7-15

[4]
Progressive Multifocal Leukoencephalopathy in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Case Study.

J Adv Pract Oncol. 2025-5-6

[5]
CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges.

Adv Biomed Res. 2025-4-30

[6]
Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer.

Neurooncol Adv. 2025-3-19

[7]
Nano-immunotherapy: Merging immunotherapy precision with nanomaterial delivery.

iScience. 2025-3-30

[8]
CAR-T cell therapy in rheumatic diseases: a review article.

Clin Rheumatol. 2025-4-26

[9]
Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.

Drug Saf. 2025-3-19

[10]
Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study.

Front Immunol. 2025-2-26

本文引用的文献

[1]
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.

Blood Adv. 2022-11-8

[2]
Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.

Front Pharmacol. 2020-5-4

[3]
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.

Blood. 2020-5-7

[4]
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.

Front Immunol. 2019-11-12

[5]
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.

Front Oncol. 2019-11-7

[6]
CAR T Cell Toxicity: Current Management and Future Directions.

Hemasphere. 2019-3-29

[7]
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.

Blood. 2019-12-12

[8]
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.

Sci Transl Med. 2019-7-3

[9]
Managing the toxicities of CAR T-cell therapy.

Hematol Oncol. 2019-6

[10]
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations.

Clin Transl Immunology. 2019-5-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索